Fast and noise-suppressed incoherent coded aperture correlation holographic imaging is proposed, which is utilized by employing an annular sparse coded phase mask together with adaptive phase-filter cross-correlation reconstruction method. Thus the proposed technique here is coined as adaptive interferenceless coded aperture correlation holography (AI-COACH). In AI-COACH, an annular sparse coded phase mask is first designed and generated by the Gerchberg-Saxton algorithm for suppressing background noise during reconstruction. In order to demonstrate the three-dimensional and sectional imaging capabilities of the AI-COACH system, the imaging experiments of 3D objects are designed and implemented by dual-channel optical configuration. One resolution target is placed in the focal plane of the system as input plane and ensured Fourier transform configuration, which is employed as reference imaging plane, and moved the other resolution target to simulate different planes of a three-dimensional object. One point spread hologram (PSH) and multiple object-holograms without phase-shift at different axial positions are captured by single-exposure sequentially with the annular sparse CPMs. A complex-reconstruction method is developed to obtain adaptively high-quality reconstructed images by employing the cross-correlation of PSH and OH with optimized phase filter. The imaging performance of AI-COACH is investigated by imaging various type of objects. The research results show that AI-COACH is adaptive to different experimental conditions in the sense of autonomously finding optimal parameters during reconstruction procedure and possesses the advantages of fast and adaptive imaging with high-quality reconstructions.
BackgroundLipoid congenital adrenal hyperplasia (LCAH) is a rare and severe disorder that is caused by mutations in the steroidogenic acute regulatory protein (StAR). Non-classic LCAH is defined as late-onset glucocorticoid deficiency and even complete male external genitalia in 46,XY individuals. However, to date, few cases of non-classic LCAH have been reported.MethodsIt was attempted to describe the clinical characteristics of a male child with complete male external genitalia in terms of age of onset, adrenal function, and biochemical indicators. Previously reported cases were also reviewed to investigate the relationship of age of onset with enzymatic activity in non-classic LCAH.ResultsThe patient with complete male external genitalia was diagnosed with non-classic LCAH, in which the reason for his referral to a local hospital at the of age 1.25 years was progressive skin hyperpigmentation, and plasma adrenocorticotropic hormone (ACTH) level was elevated to higher than 1,250 pg/ml. The compound heterozygous mutations c.772C>T/c.562C>T in STAR gene were identified via genetic testing. The literature review resulted in identification of 47 patients with non-classic LCAH from 36 families. The mutational analysis showed that c.562C>T mutation was prevalent in patients with non-classic LCAH, accounting for 37.2% of the total mutant alleles, which could reflect the founder effect on the non-classic LCAH population. In total, 28 46,XY patients were reported, including 22 (78.5%) cases with complete male external genitalia and six (21.5%) cases with different degrees of hypospadias.ConclusionThe clinical phenotypes of non-classic LCAH are highly variable. Routine physical examination, laboratory measurement, genetic testing, and, importantly, enzymatic activity assay may facilitate the early diagnosis of non-classic LCAH. The age of primary adrenal insufficiency (PAI) onset may not be a diagnostic basis for non-classic LCAH, and enzymatic activity assay determination may be more effective.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.